Trial Results: In a mid‑stage (Phase II) trial, the experimental obesity drug elecoglipron produced an average 10.5% reduction in body weight after 26 weeks of treatment. Patients receiving the highest once‑daily dose experienced an 11.8% weight loss after 36 weeks, the full duration of the study, indicating that weight loss continued throughout the trial period.
Regulatory Progress: AstraZeneca announced in February that the trial met its primary endpoints and would proceed to late‑stage (Phase III) trials. Detailed efficacy data were presented at the American Diabetes Association (ADA) scientific meeting in New Orleans.
Competitive Landscape: Novo Nordisk’s approved obesity medication Wegovy achieved approximately 14% weight loss in its pivotal trials, while Eli Lilly’s experimental pill Foundayo showed a 12% reduction in a late‑stage study. Roche’s mid‑stage obesity injection enicepatide reported a 22.7% weight loss after 48 weeks, comparable to Lilly’s Zepbound, which delivered over 20% loss after 72 weeks.
Market Reaction: Following the release, AstraZeneca’s share price fell 0.45%, while Eli Lilly rose 1.57%, Novo Nordisk declined 4.19%, and Roche dropped 1.02%.
